Joincare Pharmaceutical Group IndustryLtd Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Joincare Pharmaceutical Group IndustryLtd wird ein jährliches Gewinn- und Umsatzwachstum von 12.5% bzw. 7.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.9% betragen.

Wichtige Informationen

11.8%

Wachstumsrate der Gewinne

11.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.6%
Wachstumsrate der Einnahmen	7.6%
Zukünftige Eigenkapitalrendite	10.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Aug 13

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Jun 23

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

May 31

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Apr 09

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Mar 04

Gewinn- und Umsatzwachstumsprognosen

SHSE:600380 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	19,547	1,890	N/A	4,059	3
12/31/2025	18,427	1,712	N/A	3,792	4
12/31/2024	17,061	1,526	N/A	4,280	4
6/30/2024	16,161	1,404	3,286	4,409	N/A
3/31/2024	16,427	1,420	3,519	4,653	N/A
12/31/2023	16,646	1,443	2,799	3,929	N/A
9/30/2023	16,782	1,460	2,903	3,829	N/A
6/30/2023	17,298	1,517	2,383	3,332	N/A
3/31/2023	17,044	1,505	2,239	3,354	N/A
12/31/2022	17,143	1,503	2,830	3,978	N/A
9/30/2022	16,982	1,446	2,014	3,551	N/A
6/30/2022	16,633	1,442	2,057	3,720	N/A
3/31/2022	16,416	1,422	1,468	2,940	N/A
12/31/2021	15,904	1,328	1,042	2,563	N/A
9/30/2021	15,352	1,202	1,387	2,662	N/A
6/30/2021	14,881	1,132	1,369	2,522	N/A
3/31/2021	14,479	1,207	2,005	3,037	N/A
12/31/2020	13,522	1,120	2,195	3,025	N/A
9/30/2020	12,792	1,043	1,813	2,515	N/A
6/30/2020	12,171	1,024	1,785	2,430	N/A
3/31/2020	11,826	869	1,564	2,239	N/A
12/31/2019	11,980	894	1,609	2,312	N/A
9/30/2019	11,858	837	1,949	2,614	N/A
6/30/2019	11,741	820	2,055	2,701	N/A
3/31/2019	11,536	779	1,445	2,059	N/A
12/31/2018	11,204	699	1,171	1,826	N/A
9/30/2018	11,208	749	940	1,593	N/A
6/30/2018	11,083	2,232	899	1,518	N/A
3/31/2018	11,030	2,167	N/A	1,790	N/A
1/1/2018	10,779	2,133	N/A	1,870	N/A
9/30/2017	10,562	2,103	N/A	1,690	N/A
6/30/2017	10,254	521	N/A	1,713	N/A
3/31/2017	10,125	484	N/A	1,779	N/A
12/31/2016	9,722	451	N/A	1,645	N/A
9/30/2016	9,546	346	N/A	1,699	N/A
6/30/2016	9,373	337	N/A	1,388	N/A
3/31/2016	8,881	393	N/A	1,354	N/A
12/31/2015	8,642	412	N/A	1,265	N/A
9/30/2015	8,317	492	N/A	1,132	N/A
6/30/2015	8,031	487	N/A	1,125	N/A
3/31/2015	7,802	412	N/A	968	N/A
12/31/2014	7,418	354	N/A	979	N/A
9/30/2014	7,413	319	N/A	700	N/A
6/30/2014	6,869	298	N/A	604	N/A
3/31/2014	6,463	282	N/A	717	N/A
12/31/2013	6,220	274	N/A	636	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600380Das prognostizierte Gewinnwachstum (12.5% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: 600380Die Erträge des Unternehmens (12.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (22.7% pro Jahr).

Hohe Wachstumserträge: 600380Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 600380Die Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 600380Die Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600380Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.9%).

Joincare Pharmaceutical Group IndustryLtd Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investor sentiment improves as stock rises 24%

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 2Q 2023)

Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Business And Shares Still Trailing The Market

Dividend of CN¥0.18 announced

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

We Think Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Can Manage Its Debt With Ease

Shareholders Will Probably Hold Off On Increasing Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation For The Time Being

Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 07, 2024

First quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in 1Q 2023)

Joincare Pharmaceutical Successfully Completes TG-1000 Phase III Study

Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS exceeds analyst expectations

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investors Don't See Light At End Of Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Tunnel

Investor sentiment improves as stock rises 15%

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 03, 2024

Now 22% undervalued after recent price drop

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.18 in 2Q 2022)

New minor risk - Shareholder dilution

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2023 Results on Aug 24, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) commences an Equity Buyback for CNY 600 million worth of its shares, under the authorization approved on November 18, 2022.

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.16 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021)

Less than half of directors are independent

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.20 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.46 in FY 2019)

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥12.67

New 90-day low: CN¥13.96

New 90-day low: CN¥14.59

Third quarter earnings released

New 90-day low: CN¥16.46

First half earnings released

Joincare Pharmaceutical Group Industry Co.,Ltd. announced that it expects to receive CNY 2.1727605 billion in funding from Hillhouse Capital Management, Ltd.

Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken